Immune System Efficiency in Cancer and the Microbiota Influence
- 15 February 2021
- journal article
- review article
- Published by S. Karger AG in Pathobiology
- Vol. 88 (2), 170-186
- https://doi.org/10.1159/000512326
Abstract
The immune system plays a critical role in preventing cancer development and progression. However, the complex network of cells and soluble factor that form the tumor microenvironment (TME) can dictate the differentiation of tumor-infiltrating leukocytes and shift the antitumor immune response into promoting tumor growth. With the advent of cancer immunotherapy, there has been a reinvigorated interest in defining how the TME shapes the antitumor immune response. This interest brought to light the microbiome as a novel player in shaping cancer immunosurveillance. Indeed, accumulating evidence now suggests that the microbiome may confer susceptibility or resistance to certain cancers and may influence response to therapeutics, particularly immune checkpoint inhibitors. As we move forward into the age of precision medicine, it is vital that we define the factors that influence the interplay between the triad immune system-microbiota-cancer. This knowledge will contribute to improve the therapeutic response to current approaches and will unravel novel targets for immunotherapy.Keywords
This publication has 213 references indexed in Scilit:
- ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophagesCell Research, 2013
- Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor ImmunityPLOS ONE, 2013
- Gut microbiota-derived propionate reduces cancer cell proliferation in the liverBritish Journal of Cancer, 2012
- Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic LungCancer Cell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous MalignancyImmunity, 2008
- Immune surveillance: a balance between protumor and antitumor immunityCurrent Opinion in Genetics & Development, 2008
- Intrinsic tumour suppressionNature, 2004